RANI

Rani Therapeutics Holdings, Inc. [RANI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RANI Stock Summary

Top 10 Correlated ETFs

RANI

Top 10 Correlated Stocks

RANI

In the News

RANI Financial details

Company Rating
-
Market Cap
270.85M
Income
-33.97M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
140
Optionable
No
Shortable
Yes
Earnings
20 Mar 2024
P/E
-1.81
Forward P/E
-
PEG
0.36
P/S
-
P/B
4.57
P/C
-
P/FCF
-4.65
Quick Ratio
8.24
Current Ratio
8.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.33
EPS next Y
-
EPS next Q
-
EPS this Y
-50%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.3%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-25%
-
-
-
-
SMA20
-27.62%
SMA50
210.2%
SMA100
230.43%
Inst Own
-
Inst Trans
-
ROA
-63%
ROE
-162%
ROC
-1.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.82-5.79
52W High
-73.1%
52W Low
+34.5%
RSI
40.46
Rel Volume
39.8
Avg Volume
82.44K
Volume
3.28M
Perf Week
-16.98%
Perf Month
-7.24%
Perf Quarter
170.73%
Perf Half Y
134.85%
-
-
-
-
Beta
0.916
-
-
Volatility
0.08%, 0.3%
Prev Close
-8.5%
Price
1.345
Change
-13.78%

Something similar

Top by Market Cap
NVDA
FB2A.DE
LLY.SW
FXAIX
NVD.DE
Top Correlated ETFs
9400.SR
XCS2.L
9401.SR
KSA
FLSA
Top Correlated Stocks
AATC
POLA
XGN
GP
TTD
Similar Market Cap
ALYA.TO
EDAP
NAIT.L
GWR.TO
ONELIFECAP.NS

Company Profile

Healthcare Biotechnology
  • Volume Average 82.44K
  • Market Capitalization 270.85M
  • Employee 140
  • CEO Mr. Talat Imran
  • Headquarters San Jose,CA,US
  • IPO Date 2021-07-30
  • Website https://www.ranitherapeutics.com

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.